Painter, Corrie A.
Jain, Esha http://orcid.org/0000-0003-1201-2052
Tomson, Brett N.
Dunphy, Michael
Stoddard, Rachel E.
Thomas, Beena S.
Damon, Alyssa L.
Shah, Shahrayz
Kim, Dewey
Gómez Tejeda Zañudo, Jorge
Hornick, Jason L.
Chen, Yen-Lin
Merriam, Priscilla
Raut, Chandrajit P.
Demetri, George D.
Van Tine, Brian A.
Lander, Eric S.
Golub, Todd R. http://orcid.org/0000-0003-0113-2403
Wagle, Nikhil http://orcid.org/0000-0003-3332-9438
Funding for this research was provided by:
This research was supported by anonymous philanthropic support to the Broad Institute.
Article History
Received: 10 September 2019
Accepted: 23 December 2019
First Online: 10 February 2020
Competing interests
: C.A.P. is a nominal stockholder in Supernus Pharmaceuticals. C.A.P. has received sponsored research support from Eisai Inc. J.L.H. is a consultant to Eli Lilly and Epizyme. G.D.D. reports the following interests: grants, personal fees, non-financial support and travel support to consulting meetings from Novartis, Bayer, Roche, Epizyme and Daiichi-Sankyo; grants, personal fees and travel support to consulting meetings from Pfizer; personal fees and travel support to consulting meetings from EMD-Serono; personal fees from Sanofi; grants and personal fees from Ignyta; grants, personal fees and travel support to consulting meetings from Loxo Oncology; grants, personal fees and non-financial support from AbbVie; personal fees and travel support to consulting meetings from Mirati Therapeutics; personal fees and travel support to consulting meetings from WIRB Copernicus Group; personal fees from ZioPharm; personal fees from Polaris Pharmaceuticals; personal fees and travel support to consulting meetings from M.J. Hennessey/OncLive; grants, personal fees and travel support to consulting meetings from Adaptimmune; grants from GlaxoSmithKline; personal fees, minor equity, and travel support to Board meetings from Blueprint Medicines, where he serves as a member of the Board of Directors; personal fees and minor equity options from Merrimack Pharmaceuticals, where he serves as a member of the Board of Directors; personal fees and minor equity from G1 Therapeutics; personal fees, minor equity options and travel support to consulting meetings from CARIS Life Sciences; minor equity options from Bessor Pharmaceuticals; minor equity options from ERASCA Pharmaceuticals; personal fees and travel support to consulting meetings from CHAMPIONS Oncology; grants and personal fees from Janssen; grants, personal fees, travel support to consulting meetings, and non-financial support from PharmaMar. In addition, G.D.D. has a use patent on imatinib for GIST, licensed to Novartis with royalties paid to the Dana-Farber Cancer Institute. E.S.L. serves on the Board of Directors for Codiak BioSciences and Neon Therapeutics, and serves on the Scientific Advisory Board of F-Prime Capital Partners and Third Rock Ventures; he is also affiliated with several non-profit organizations including serving on the Board of Directors of the Innocence Project, Count Me In, and Biden Cancer Initiative, and the Board of Trustees for the Parker Institute for Cancer Immunotherapy. E.S.L. has served and continues to serve on various federal advisory committees. T.R.G. serves or has recently served as a scientific adviser to Foundation Medicine, Inc. (wholly owned by Roche), GlaxoSmithKline, plc, Sherlock Biosciences, Inc., and FORMA Therapeutics, Inc. N.W. was previously a stockholder and consultant for Foundation Medicine, Inc., has been a consultant/advisor for Novartis and Eli Lilly, and has received sponsored research support from Novartis and Puma Biotechnology. None of the for-profit entities had any role in the conceptualization, design, data collection, analysis, decision to publish, or preparation of the manuscript.